Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 16, 2025Journal of Clinical MedicineOpen Access

Extended Real-World Efficacy of Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: 9-Month Follow-Up Results

View Full Paper
Ask AI
Bookmark
Share

Authors

MHMichael HafnerTHTina HeroldAKAlexander Kufner

Discussion

Loading...

Member takes

Overview

Retrospective analysis reports improved BCVA and CST in macular edema patients, suggesting faricimab's effectiveness as an alternative treatment.

Key Points

  • Switching to faricimab improved best-corrected visual acuity in therapy-resistant patients, maintaining gains at nine months.
  • The median central subfield thickness decreased significantly from baseline to month three, with effects sustained at nine months.
  • Intraretinal fluid presence diminished dramatically from baseline to month nine, highlighting faricimab's impact on retinal health.
  • Extension of treatment intervals suggests better management of therapy-resistant macular edema, with no reported adverse events.

Cite This Study

Hafner et al. (2025) studied this question.

synapsesocial.com/papers/68f17f111f11f0e857c536f4https://doi.org/10.3390/jcm14207197
View Full Paper
Ask AI
Bookmark
Share